PHARMA/BIOTECH: A Cure for Australian Investment Pain?
Bloomberg has the pleasure of inviting you to an afternoon of interesting discussion with market experts including a special keynote from Paul Perreault, Chief Executive Officer and Managing Director of CSL.
The S&P/ASX 300 Pharmaceutical and Biotechnology index has risen almost 10% in the past 12 months versus a 12% fall in the broader equity index. With the index surging 162% over the past five years investors are understandably eager to include pharma and biotech as constituents within their portfolios.
We look at exploring some of the challenges and opportunities for the sector:
How can financial professionals reliably value companies that claim they are close to a cure for cancer?
What resources are available to assess such investment opportunities?
Can pharmaceutical and biotech companies better sell their stories to Australian investors who may not be knowledgeable on the sector?
We hope you can join us for some lively discussions followed by a networking reception.
When & Where
Tuesday, April 12
4:00pm - 6:00pm
1 Parliament Place